The SME initial public offering (IPO) of Punjab-headquartered multi-specialty tertiary care hospital operator ABH Healthcare Limited (operating under the clinical brand Anil Baghi Hospital) concluded …
The SME initial public offering (IPO) of Punjab-headquartered multi-specialty tertiary care hospital operator ABH Healthcare Limited (operating under the clinical brand Anil Baghi Hospital) concluded its public bidding window across national bourses today, Thursday, August 27, 2026.
Carrying an aggregate issue size of ₹34.98 crore set within an official price band parameter of ₹96.00 to ₹102.00 per share, the public offer marks a 100% fresh primary equity issuance to fund bank debt repayment, operational working capital expansion, and potential hospital acquisitions.
Building on steady participation across earlier sessions, the final trading day saw retail individual investors and institutional buyers push the issue across the finish line into full oversubscription. By the close of trading at 5:00 PM IST across the NSE SME platform, central exchange matching registries compiled valid electronic application tokens for 46,81,200 equity shares against a net public offer pool of 32,56,800 equity shares (excluding the market maker quota of 1,72,800 shares).
This pushed the final cumulative subscription baseline to 1.44 times (144% coverage).
Qualified Institutional Buyers (QIBs) led the overall category coverage at 8.37 times, while retail individual investors drove volume to 1.69 times, and Non-Institutional Investors (NII / HNI) closed at 0.29x.
At the upper price band cap of ₹102 per share, the offer has mobilized an aggregate primary capital demand value of ₹47.75 crore clearing through central registries.
With the bidding window officially closed, market attention shifts toward the basis of allotment finalization, demat credit of shares, unlisted grey market trends, and the upcoming stock exchange debut scheduled for Tuesday, September 1, 2026.
Here is an extended, plain-English human breakdown covering final subscription metrics, unlisted grey market trends, business operations across multi-specialty tertiary healthcare, financial performance, capital deployment plans, valuation parameters, and the upcoming allotment guide.
1. Final Subscription Data Breakdown
By 5:00 PM on the final day, central exchange processing registries compiled total valid application orders worth ₹47.75 crore (calculated at the upper price band cap of ₹102 per share), covering 144% of the net public offer.
The table below summarizes the closing performance across all investor categories:
+-----------------------------------------------------------------------------------+ | ABH HEALTHCARE LIMITED: FINAL SUBSCRIPTION DATA | +-------------------+-----------------+------------------+------------------+-------+ | Category | Shares Offered | Shares Bid For | Final Sub (x) | Value | +-------------------+-----------------+------------------+------------------+-------+ | QIB (Institutions)| 1,99,200 | 16,66,800 | 8.37x | ₹17.00Cr | NII / HNI (Wealth)| 15,28,800 | 4,36,800 | 0.29x | ₹4.46Cr | Retail (RII) | 15,28,800 | 25,77,600 | 1.69x | ₹26.29Cr | Market Maker | 1,72,800 | — | — | — | +-------------------+-----------------+------------------+------------------+-------+ | Total Net Offer | 32,56,800 | 46,81,200 | 1.44x | ₹47.75Cr +-------------------+-----------------+------------------+------------------+-------+
Analyzing the Category Inflows:
- Qualified Institutional Buyers (QIB - 8.37x): Institutional desks maintained solid institutional backing throughout the offer with bids placed for 16,66,800 shares worth ₹17.00 crore against the 1.99 lakh shares offered in their net allocation slice, holding firmly at 8.37 times coverage.
- Retail Individual Investors (RII - 1.69x): Everyday retail accounts added significant bids on the final day, climbing from 14.38 lakh shares on Day 3 to 25,77,600 shares (1,074 application lots) worth ₹26.29 crore against 15.29 lakh shares offered, taking retail coverage to 1.69 times. Under the issue rules for this SME offer, retail applicants faced a minimum lot requirement of 2 lots (2,400 shares), requiring an upfront layout of ₹2,44,800 at ₹102 per share.
- Non-Institutional Investors (NII / HNI - 0.29x): High-net-worth wealth accounts and family offices registered orders for 4,36,800 shares worth ₹4.46 crore against 15.29 lakh shares offered, reaching 29% coverage.
- Market Maker Reserved Block: A dedicated block of 1,72,800 shares (~₹1.76 crore) is allocated to the designated market maker (Rikhav Securities Limited) to provide secondary market quote liquidity support post-listing.
2. Unlisted Grey Market Premium (GMP) & Market Sentiment
In the unofficial grey market, sentiment surrounding ABH Healthcare remains steady:
- Fixed Upper Price Cap Anchor: ₹102.00 per share
- Current Grey Market Premium (GMP): Tracking around +₹20.00 to +₹25.00 per share (~19.6% to 24.5% over issue price)
- Estimated Listing Price Range: Expected debut counter level of ₹122.00 to ₹127.00 per share
- Projected Listing Gain Margin: Indicating an immediate estimated listing upside of ~19.61% to 24.51%
- Retail Minimum Application Lot Size: 2 Lots / 2,400 Shares (Minimum Investment: ₹2,44,800)
What Is Driving Grey Market Optimism?
- Established Tertiary Healthcare Moat: Operating the NABH-accredited 150-bed Anil Baghi Hospital in Ferozepur, Punjab across 25 medical specialties gives the hospital a dominant regional healthcare footprint.
- 100% Fresh Issue Deleveraging: Deploying ₹17.00 crore toward debt repayment directly reduces annual finance overheads and enhances net profit margins post-listing.
(Note: Grey market premiums represent informal, off-exchange quotes traded among dealers. They fluctuate based on daily market mood and should not be treated as a guaranteed listing price.)
3. Business Overview: What Does ABH Healthcare Do?
Incorporated in 2021 and rooted in a medical legacy dating back several decades under founder Dr. Kamal Baghi, ABH Healthcare Limited is a multi-specialty healthcare provider headquartered in Ferozepur, Punjab, operating under the established brand Anil Baghi Hospital.
The company operates a NABH-accredited 150-bed multi-specialty tertiary care hospital offering clinical treatment across 25 medical specialties, including cardiology, neurosurgery, minimally invasive spine surgery, nephrology, oncology, orthopedics, gastroenterology, and critical care.
+-----------------------------------------------------------------------------------+ | ABH HEALTHCARE BUSINESS AT A GLANCE | +-----------------------------------+-----------------------------------------------+ | Hospital Brand Name | Anil Baghi Hospital (NABH Accredited) | +-----------------------------------+-----------------------------------------------+ | Core Focus Area | Multi-Specialty Tertiary Healthcare Services | +-----------------------------------+-----------------------------------------------+ | Operational Bed Capacity | 150 Beds (Capex: ₹29.61 Lakh / Operational Bed)| +-----------------------------------+-----------------------------------------------+ | Clinical Specialties Offered | 25 Specialties (Cardiology, Neuro, Nephro) | +-----------------------------------+-----------------------------------------------+ | Medical Staff Strength | 37 Doctors and 101 Trained Nurses | +-----------------------------------+-----------------------------------------------+ | Primary Operational Hub | Ferozepur, Punjab | +-----------------------------------+-----------------------------------------------+ | Key Promoters & Leadership | Dr. Kamal Baghi, Dr. Saurabh Baghi, Dr. Vaishali| +-----------------------------------+-----------------------------------------------+
Core Competitive Moats:
1. Comprehensive 25-Specialty Tertiary Care Setup
Anil Baghi Hospital provides advanced clinical care across 25 specialties, equipped with advanced catheterization labs (Cath Lab), modular surgical operating theaters, dialysis units, and intensive care units (ICU), serving patients across southwestern Punjab and neighboring border districts.
2. Extensive Institutional & TPA Empanelment
The hospital is empaneled with over 30 private and public health insurance companies, Third-Party Administrators (TPAs), and key government healthcare schemes—including Ayushman Bharat - MJSY, ECHS (Ex-Servicemen Contributory Health Scheme), Railways, and FCI—ensuring steady patient footfalls.
3. Low Capex Per Bed & Expanding ARPOB
Operating with a low capital outlay of ~₹29.61 lakh per operational bed, the hospital has steadily expanded its Average Revenue Per Occupied Bed (ARPOB) to nearly ₹20,000 in FY26 alongside scaling inpatient (IPD) admissions.
4. Detailed Financial Performance (FY24 to FY26)
An audit of the company's restated consolidated financial statements shows steady revenue expansion and expanding operating profitability over the last three fiscal years.
+-----------------------------------------------------------------------------------+ | ABH HEALTHCARE: 3-YEAR FINANCIAL PERFORMANCE | +-------------------------------+-------------------+-------------------+-----------+ | Financial Metric (₹ in Cr) | FY24 | FY25 | FY26 | +-------------------------------+-------------------+-------------------+-----------+ | Total Income / Revenue | 41.39 | 49.32 | 52.59 | | Operating EBITDA | 6.89 | 13.20 | 14.72 | | EBITDA Margin (%) | 16.65% | 26.76% | 27.99% | | Net Profit After Tax (PAT) | 1.66 | 5.35 | 5.64 | | PAT Margin (%) | 4.01% | 10.85% | 10.72% | | Total Assets | 51.35 | 63.90 | 85.27 | | Total Debt / Borrowings | 30.59 | 33.78 | 45.75 | | Net Worth | 6.30 | 11.60 | 17.27 | | Return on Net Worth (RoNW %) | 26.35% | 46.12% | 39.07% | | Return on Capital Employed % | 14.20% | 21.80% | 19.09% | +-------------------------------+-------------------+-------------------+-----------+
(Source: Restated Consolidated Financial Statements in Prospectus & KPI Filings)
Key Financial Observations:
- Consistent Revenue Growth: Total income expanded from ₹41.39 crore in FY24 to ₹49.32 crore in FY25, before reaching ₹52.59 crore in FY26 (a 2-year growth of 27.1%). Growth was driven by higher IPD patient admissions and expanded cardiology procedures.
- Expanding Operating EBITDA (27.99%): Operating EBITDA expanded to ₹14.72 crore in FY26 (up from ₹6.89 crore in FY24), with EBITDA margins stabilizing at 27.99%.
- Net Profit Scaling: Net profit after tax (PAT) rose from ₹1.66 crore in FY24 to ₹5.35 crore in FY25, and reached ₹5.64 crore in FY26, delivering a PAT margin of 10.72%.
- Strong Capital Return Ratios: The company delivered a Return on Net Worth (RoNW) of 39.07% in FY26.
5. Structure of the Offer & Objects of the Issue
The ₹34.98 crore public offer is structured entirely as a 100% fresh primary capital issuance:
+-----------------------------------------------------------------------------------+ | IPO CAPITAL STRUCTURE BREAKDOWN | +-----------------------------------+-----------------------------------------------+ | Total Issue Size | ₹34.98 Crore (34,29,600 Equity Shares) | +-----------------------------------+-----------------------------------------------+ | Fresh Issue Component | ₹34.98 Crore (100% Fresh Capital Issue) | +-----------------------------------+-----------------------------------------------+ | Offer for Sale (OFS) Component | ₹0.00 (No Selling Shareholders) | +-----------------------------------+-----------------------------------------------+ | Price Band | ₹96.00 to ₹102.00 per share | +-----------------------------------+-----------------------------------------------+ | Face Value | ₹10 per share | +-----------------------------------+-----------------------------------------------+ | Market Maker Reserved Block | 1,72,800 Shares (₹1.76 Crore Value) | +-----------------------------------+-----------------------------------------------+ | Net Offer to Public | 32,56,800 Shares (₹33.22 Crore Value) | +-----------------------------------+-----------------------------------------------+ | Lead Manager (BRLM) | Fedex Securities Private Limited | +-----------------------------------+-----------------------------------------------+ | Registrar to the Issue | Bigshare Services Private Limited | +-----------------------------------+-----------------------------------------------+
How Will Fresh Primary Capital Be Deployed?
Because there is no Offer for Sale (OFS), 100% of the proceeds move directly onto the company balance sheet:
- Repayment / Prepayment of Borrowings (₹17.00 Crore / 48.6%): Paying down existing bank term loans and borrowings to lower annual finance costs.
- Working Capital Requirements (₹5.00 Crore / 14.3%): Procuring medical consumables, pharmaceuticals, and managing billing credit cycles with TPAs and government health schemes.
- Inorganic Growth via Acquisitions & General Corporate Purposes (₹12.98 Crore / 37.1%): Exploring bolt-on hospital acquisitions in surrounding districts and general corporate operations.
6. Valuation Analysis & Peer Group Comparison
At the upper price band cap of ₹102 per share, ABH Healthcare is priced at a trailing Price-to-Earnings (P/E) multiple of 14.47x based on pre-issue FY26 basic EPS of ₹7.05 (and 20.69x based on post-issue diluted capital), establishing a post-issue corporate market capitalization of approximately ₹116.58 crore.
Let's compare this with listed regional hospital and healthcare peers in India:
+-----------------------------------------------------------------------------------+ | PEER GROUP VALUATION COMPARISON | +-----------------------------------+--------------------+--------------------------+ | Company Name | Trailing P/E (x) | Primary Focus / Model | +-----------------------------------+--------------------+--------------------------+ | ABH Healthcare (At ₹102) | ~20.69x (Post-IPO) | 150-Bed Multi-Specialty | | Sangani Hospitals Ltd | ~32.95x | Regional Hospital Chain | | Asarfi Hospital Ltd | ~57.75x | Multi-Specialty Hospital | | Maitreya Medicare Ltd | ~66.90x | Regional Healthcare Unit | +-----------------------------------+--------------------+--------------------------+
Valuation Summary:
At ~20.7x post-issue FY26 trailing earnings, ABH Healthcare enters the market at a noticeable valuation discount compared to listed SME healthcare peers like Sangani Hospitals (~33x P/E) and Asarfi Hospital (~58x P/E).
With revenue at ₹52.59 crore, 28% EBITDA margins, 39.07% RoNW returns, and ₹17 crore in fresh capital funding balance sheet deleveraging, the valuation leaves a fair fundamental margin of safety for incoming public investors.
7. Core Strengths vs. Key Business Risks
Investors evaluating this SME healthcare issue should consider the following operational factors:
Key Strengths:
- 100% Fresh Issue Structure: No promoter cash-out; ₹17 crore goes directly toward debt reduction.
- Disciplined Valuation (~20.7x Post-IPO P/E): Priced favorably relative to listed hospital peers trading above 30x–60x P/E.
- Solid QIB Backing (8.37x): Strong institutional participation supporting the issue.
- NABH-Accredited 150-Bed Infrastructure: Established brand presence across 25 specialties in Ferozepur, Punjab.
Key Risk Factors:
- Single-Location Dependency: Operates exclusively out of its hospital in Ferozepur, Punjab, making revenues sensitive to local dynamics.
- High Working Capital Exposure to Government Schemes: TPA and government scheme receivables can involve extended reimbursement cycles.
- High Retail Application Threshold: The minimum investment required for retail applicants is ₹2,44,800 (2 lots / 2,400 shares), which restricts participation from smaller retail accounts.
8. Application Matrix & Final Listing Timeline
With the public offer now closed, here is the upcoming schedule for allotment finalization and listing:
- Public Bidding Window Closes: Thursday, August 27, 2026 (Status: Bidding Closed)
- Basis of Allotment Finalization: Friday, August 28, 2026
- Refund Initiations & Unblocking of Bank Funds: Monday, August 31, 2026
- Credit of Equity Shares to Demat Accounts: Monday, August 31, 2026
- Official Stock Exchange Listing (NSE SME): Tuesday, September 1, 2026
- Designated Lead Manager: Fedex Securities Private Limited
- Designated Registrar: Bigshare Services Private Limited
How to Check Your Allotment Status:
When allotment details go live on Friday, August 28, 2026, applicants can check their status by entering their PAN card number or Application ID on the Bigshare Services Portal or directly on the official NSE website under the SME allotment section.
Conclusion
ABH Healthcare has concluded its public offering with a 1.44x overall subscription (~₹47.75 crore total primary demand), anchored by 8.37x institutional QIB participation and 1.69x retail coverage.
With ₹17 crore in fresh capital moving directly into bank debt reduction, ₹52.59 crore in revenue scale, 39.07% RoNW returns, and an attractive ~20.7x post-issue trailing P/E valuation, the company is set for its SME debut on the NSE SME platform on Tuesday, September 1.
Post Excerpt
A complete final day analysis of the ₹34.98 crore ABH Healthcare (Anil Baghi Hospital) SME IPO. Bids closed at 1.44x overall, led by 8.37x in QIBs and 1.69x in retail as total primary demand reached ₹47.75 crore. Read our full review of company financials (₹52.59 Cr revenue, ₹5.64 Cr PAT), 150-bed hospital moats, grey market trends (+₹20–₹25), ₹17 crore debt reduction plans, allotment schedule, and valuation (20.69x post-issue P/E) ahead of its September 1 listing.
